An H. Nguyen

An H. Nguyen

Auto-generated profile, based on publicly available information

An H. Nguyen

Department of Oncology Science, The University of Oklahoma College of Medicine, Stephenson Cancer Center, Oklahoma City, Oklahoma

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
SMSimbarashe Mazambani
Simbarashe Mazambani
SPSeong-Ho Park
Seong-Ho Park
Joshua ChoeJoshua Choe
Joshua Choe
ANAn H. Nguyen
An H. Nguyen
BLBok-Soon Lee
Bok-Soon Lee
TKTae Hoon Kim
Tae Hoon Kim
Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)–mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer–specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo, partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. Significance: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.

6 June 2025
Verified
Other
Open access
SMSimbarashe Mazambani
Simbarashe Mazambani
SPSeong-Ho Park
Seong-Ho Park
Joshua ChoeJoshua Choe
Joshua Choe
ANAn H. Nguyen
An H. Nguyen
BLBok-Soon Lee
Bok-Soon Lee
TKTae Hoon Kim
Tae Hoon Kim
GLUT1 inhibition enhances cytotoxic oxidative stress in human HNSCC cell lines. A,In vitro proliferation and immunoblot analyses of shScramble (shScr) and shRNA-mediated KD of GLUT1 (shGLUT1) in HNSCC cell line FaDu (n = 4 for each group). Two-way ANOVA. ****, P < 0.0001 (left). Immunoblot validation of shRNA-mediated KD of GLUT1 in FaDu cells (right). B, Relative glucose uptake and (C) intracellular ROS measurement in shScr and shGLUT1 FaDu cells (n = 3 for each group). Two-tailed t test. ***, P < 0.001; **, P < 0.01. D,In vitro proliferation of shScr, shGLUT1, and shGLUT1 + NAC (5 mmol/L) in HNSCC cell line SCC-61 (n = 4 for each group). Two-way ANOVA. ****, P < 0.0001 (left). Immunoblot validation shRNA-mediated KD of GLUT1 in SCC-61 cells (right). E, Intracellular ROS measurement of shScr, shGLUT1, and shGLUT1 + NAC (5 mmol/L) in SCC-61 cells (n = 3 for each group). Two-tailed t test. ****, P < 0.0001; ***, P < 0.001. F and G,In vitro proliferation of FaDu cells treated with GLUT1 inhibitors, WZB117 (0–40 μmol/L) or BAY-876 (0–100 nmol/L; n = 3 for each group). H and I,In vitro proliferation of FaDu (H) or SCC-61 (I) treated with WZB117 (30 μmol/L) or BAY-876 (150 nmol/L) with or without 5 mmol/L NAC treatment (n = 6 for each group). Two-way ANOVA. ****, P < 0.0001; **, P < 0.01; *, P < 0.05 (top). Intracellular H2O2 measurement of FaDu (H) or SCC-61 (I) cells treated with WZB117 (30 μmol/L) or BAY-876 (150 nmol/L) with or without 5 mmol/L NAC treatment (n = 6 for each group). Two-tailed t test. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01 (bottom). All error bars represent mean ± SEM unless otherwise noted. BAY, BAY-876; RFU, relative fluorescent unit; RLU, relative light unit; WZB, WZB117.

6 June 2025
Verified
Other
Open access
SMSimbarashe Mazambani
Simbarashe Mazambani
SPSeong-Ho Park
Seong-Ho Park
Joshua ChoeJoshua Choe
Joshua Choe
ANAn H. Nguyen
An H. Nguyen
BLBok-Soon Lee
Bok-Soon Lee
TKTae Hoon Kim
Tae Hoon Kim
GLUT1 overexpression in TCGA HNSCC tumor samples. A, TCGA mRNA-seq analyses [normalized transcripts per million (TPM) mappable reads] of GLUT1 and metabolic genes associated with glycolysis, PPP, and de novo serine biosynthesis pathway in the patients of the TCGA HNSCC cohort (n = 520) and matched normal (n = 44) tissue samples. Each dot represents one patient. Error bars represent the median ± quartile range, Mann–Whitney U test. ****, P < 0.0001. B, Top five Hallmark gene sets enriched in patients of the TCGA HNSCC cohort are compared with matched normal tissue samples by gene set enrichment analysis. C, Violin plots depicting SLC2A1 (GLUT1) mRNA expression in TCGA tumor samples stratified by lineage. Lineages are ordered by descending mean SLC2A1 expression, and HNSCC is highlighted in red. D, Violin plot comparing SLC2A1 (GLUT1) mRNA expression in TCGA HNSCC tumors with GTEx normal esophageal mucosa. Dots represent individual cell lines. Welch t test. ****, P < 0.0001. E, Heatmap indicating expression of genes enriched in the patients of the TCGA HNSCC cohort when compared with matched normal tissue samples. F and G, Immunoblot analysis and quantification of GLUT1 expression in human HNSCC tumor (n = 5) and matched normal head and neck epithelial (n = 5) tissue samples. **, P < 0.01. Error bars represent the median ± quartile range. Mann–Whitney U test. H,SLC2A1 mRNA expression from human HNSCC tumor samples (n = 8) and matched normal head and neck epithelial tissue samples (n = 7). Error bars represent the mean ± SEM. Mann–Whitney U test. ***, P < 0.001. I, Kaplan–Meier survival curves depicting OS of patients with HNSCC (n = 519) up to 120 months, stratified by SLC2A1 mRNA expression. High- and low-SLC2A1 expression groups were determined using the maximally selected rank statistic. A significant difference in OS between groups was assessed using the log-rank test, and a Cox proportional hazards model was applied to calculate the HR. ENO1, enolase 1; G6PD, glucose-6-phosphate dehydrogenase; HK2, hexokinase 2; PKM, pyruvate kinase M; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine phosphatase; SHMT2, serine hydroxymethyltransferase 2; SLC2A1, solute carrier family 2 member 1.



6 June 2025
Verified
Other
Open access
SMSimbarashe Mazambani
Simbarashe Mazambani
SPSeong-Ho Park
Seong-Ho Park
Joshua ChoeJoshua Choe
Joshua Choe
ANAn H. Nguyen
An H. Nguyen
BLBok-Soon Lee
Bok-Soon Lee
TKTae Hoon Kim
Tae Hoon Kim
Auranofin induces cytotoxicity as a pro-oxidant in HNSCC. A and B,In vitro proliferation (top) and intracellular H2O2 levels (bottom) of FaDu (A) or SCC-61 (B) cells treated with vehicle, WZB117 (20 μmol/L), auranofin (1 μmol/L), or combination of WZB117 and auranofin (n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01. C–F,In vivo tumor growth (C), tumor weights (D), images of individual tumors (E), and IHC analysis of GLUT1, pH2A.X, 4HNE, and CC3 (F) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO (n = 6) or auranofin (10 mg/kg i.p. daily; n = 6). Two-way ANOVA for tumor growth (C) and two-tailed t test for tumor weight (D). ****, P < 0.0001; ***, P < 0.001. G, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and CC3 (apoptotic cell marker) in xenografted tumors (n = 6 for each group). Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. **, P < 0.01. H,In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO (n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), auranofin (10 mg/kg i.p. daily; n = 15), or combination of WZB117 and auranofin (n = 12). Two-way ANOVA. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01. I,In vivo tumor growth of SCC-61 xenograft tumors treated with vehicle PBS/DMSO (n = 6), WZB117 (20 mg/kg i.p. daily; n = 7), auranofin (10 mg/kg i.p. daily; n = 7), or combination of WZB117 and auranofin (n = 7). Two-way ANOVA. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01. All error bars represent mean ± SEM unless otherwise noted. Scale bars, 1 mm. BAY, BAY-876; H&E, hematoxylin and eosin; RLU, relative light unit; WZB, WZB117.